Pulmonary Hypertension

Pediatric PAH Diagnosis and Management: A Clinical Roundtable

By

Tori Rodriguez, MA, LPC, AHC

The optimal treatment approach for pulmonary arterial hypertension in pediatric patients depends upon the severity and underlying etiology of the disease.

Widening the Definition and Use of Palliative Care in PAH

By

Tori Rodriguez, MA, LPC, AHC

The most recent CHEST guidelines on pulmonary arterial hypertension treatment support the integration of palliative care, noting significant improvements in outcomes observed in other pulmonary diseases, including lung cancer.

New “Old” Therapies in Pulmonary Arterial Hypertension: A Clinical Roundtable

By

Tori Rodriguez, MA, LPC, AHC

In a review of repurposing medications for pulmonary arterial hypertension treatment, dichloroacetate, metformin, and rosiglitazone/pioglitazone had the most preclinical data to support their use.

FDA to Review Drug-Device Combo for Pulmonary Arterial Hypertension Treatment

By

Steve Duffy

The FDA has accepted for review the New Drug Application for Trevyent, a drug-device combination product for the treatment of pulmonary arterial hypertension.

Sotatercept Receives Orphan Drug Status for Pulmonary Arterial Hypertension

By

Brian Park, PharmD

The FDA has granted Orphan Drug designation to sotatercept for the treatment of patients with pulmonary arterial hypertension.

New Pulmonary Hypertension Definition Clarifies Mortality Risk After Heart Transplant

By

Pulmonology Advisor Contributing Writer

The new definition of pulmonary hypertension has demonstrated validity in a study recently published in CHEST, which showed an association between elevated pulmonary vascular resistance (PVR) and increased risk for mortality within 30 days of heart transplant. This risk can be sustained even with lower pulmonary arterial pressures. This retrospective study included 32,465 adult participants…

Ralinepag Reduces Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension

By

Sheila Jacobs

Treatment with the next-generation potent prostacyclin receptor agonist ralinepag reduced pulmonary vascular resistance compared with placebo in patients with symptomatic pulmonary arterial hypertension.

Effects of Pulmonary Hypertension on Outcomes After MVR for Rheumatic Mitral Stenosis

By

Pulmonology Advisor Contributing Writer

Researchers gauged the effect of concomitant pulmonary hypertension on clinical outcomes and late-onset progression of tricuspid regurgitation after mitral valve relapse for rheumatic mitral stenosis.

Pulmonary Arterial Hypertension in Women: New Approaches to Care

By

Cardiology Advisor Contributing Writer

Investigators provide recent information on the classification, pathophysiology, diagnosis, and treatment of pulmonary arterial hypertension, focusing specifically on its impact on women.

Implantable Hemodynamic Sensor May Guide Therapy in PAH With Right-Sided HF

By

Pulmonology Advisor Contributing Writer

An implantable hemodynamic monitor safely monitored hemodynamic changes in patients with severe pulmonary arterial hypertension.

Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH

By

Pulmonology Advisor Contributing Writer

Inhaled epoprostenol delivered via high-flow nasal cannula increased oxygenation among patients with severe hypoxemia with pulmonary hypertension or right heart dysfunction.